Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 678 across all filing types
Latest filing 2025-01-16 Call Transcript
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is a notification about an upcoming earnings conference call scheduled for February 3, 2025, to discuss the company's financial performance for the quarter and nine months ended December 31, 2024. It includes details about the call, dial-in information, and mentions that the transcript and audio recording will be made available on the company's website after the call. The document does not contain actual financial data or the transcript itself, but rather serves as an announcement of the earnings call event.
2025-01-16 English
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a notification to stock exchanges about an upcoming Board Meeting scheduled for February 3, 2025, to consider and approve the un-audited financial results for the quarter and nine months ended December 31, 2024. It also mentions the reopening of the trading window and an upcoming earnings call on the same date. The document is short (1945 characters) and serves as an announcement of the meeting and related events, not the financial results themselves. It does not contain actual financial data or detailed financial analysis. Therefore, it is an announcement related to management decisions and board activities, specifically a Board/Management Information filing under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements). Hence, the appropriate classification is MANG (Board/Management Information).
2025-01-16 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to stock exchanges informing about the conclusion of a US FDA inspection at the company's manufacturing facility. It references a prior announcement and provides an update on the inspection closure. The content is an official regulatory announcement rather than a detailed report or financial statement. The document length is only 1407 characters, indicating it is a brief notice. There is no financial data, management discussion, or detailed report content. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance updates that do not fit other categories.
2025-01-16 English
Change in Management
Board/Management Information Classification · 100% confidence The document is a formal announcement addressed to stock exchanges regarding the appointment of a new Chief Executive Officer, referencing compliance with SEBI regulations. It mentions the effective date of the CEO appointment and the continuation of the Executive Chairman. There is no financial data, report, or presentation content. The document is clearly about a change in senior management, fitting the category of Board/Management Information (MANG). The document length is short and focused solely on management change, confirming the classification.
2025-01-15 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of the SEBI (Depository and Participants Regulations), 2018, issued by the Registrar and Share Transfer Agent confirming dematerialisation activities for the quarter ended December 31, 2024. It is a compliance certificate related to securities dematerialisation and does not contain financial statements, management discussion, or other report content. The document is short (3164 characters) and serves as a regulatory compliance filing rather than a financial or management report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for compliance certificates and miscellaneous regulatory announcements.
2025-01-13 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges informing about the closure of the trading window due to insider trading regulations. It mentions the upcoming declaration of Un-Audited Financial Results for the quarter and nine months ending December 31, 2024, but does not contain any financial data or the results themselves. The document is short (1446 characters) and serves as a notification rather than a report. Therefore, it is an announcement related to regulatory compliance and trading restrictions, not a financial report or earnings release. This fits best under Regulatory Filings (RNS).
2024-12-27 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.